Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006364 · ClinicalTrials.gov registry record · Phase 2
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
A Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00006364: Completed Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia, sponsored by National Cancer Institute (NCI).
NCT00006364 is a Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006364, a Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG omacetaxine mepesuccinate
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1999-11 |
| Phase | Phase 2 |
What the finished NCT00006364 record still lists
NCT00006364 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (19% higher).
The record links to 4 conditions, with Chronic Myelogenous Leukemia, BCR-ABL1 Positive appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00006364 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00006364 about?
NCT00006364 is a clinical study titled "Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia". Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die
What is the current status of trial NCT00006364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1999-11.
What conditions does trial NCT00006364 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00006364?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), omacetaxine mepesuccinate (DRUG).
Who is sponsoring clinical trial NCT00006364?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006364 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006364's enrollment target sits among peer trials
50 5th of 10 higher than 6 of 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
ACTIVE NOT RECRUITING · Phase 2
-
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
COMPLETED · Phase 2
-
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
COMPLETED · Phase 2
-
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RECRUITING · Phase 1
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia